Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Part of GSK Plc, Novartis Consumer Health SA is a Swiss company located in Basel focused on pharmaceutical preparations.

APR Applied Pharma Research SA develops and licenses healthcare products and technologies. It specializes in the development of oral and topical formulations in various healthcare regulatory areas ranging from Rx and OTC pharmaceuticals, nutraceuticals, dermocosmetics, and medical devices. The company was founded in 1990 and is headquartered in Balerna, Switzerland.

Grünenthal GmbH engages in the research and development of pharmaceutical products. It specializes in pain, gout, and inflammation. The company was founded by Hermann Wirtz in 1946 and is headquartered in Aachen, Germany.

iCeutica, Inc. manufactures pharmaceutical products. It offers SoluMatrix platform, a drug reformulation and delivery technology for poorly water-soluble compounds. This technology enables iCeutica to make significantly improved formulations of approved and development stage drugs, some of which have been shown in late stage clinical trials to work faster, at a lower dose or be delivered to the body by an alternative route. The company was founded by James Williams and Matthew Callahan in 2005 and is headquartered in Philadelphia, PA.

Ciba-Geigy AG was manufacturing pharmaceuticals. The company was merged with Sandoz Ltd. to create Novartis AG. The company was founded in 1884 and was headquartered in Basle, Switzerland.

Yung Shin Pharmaceutical Industrial Co., Ltd. engages in the manufacture and sale of pharmaceutical products. Its products include active pharmaceutical ingredients, traditional Chinese medicine, human medicine, animal medicine, food products, and medical equipment. The company was founded by Tien Te Li in 1952 and is headquartered in Taichung, Taiwan.

Troikaa Pharmaceuticals Ltd. is an Indian private company located in Ahmedabad. The firm manufactures and supplies pharmaceutical products. It was founded in 1994.

The Kobayashi Pharmaceutical Group provides a variety of products in fields such as pharmaceuticals, fragrances, dietary supplements and daily necessities. Providing products in these diverse fields is a business activity based on the broader management philosophy of “Providing Great Pleasure to People and Society” regardless of the current business domain. The current management philosophy was newly created in April 1999 by adding the meanings of “creation and innovation” and “Something New Something Different”, which are one of the characteristics of the Kobayashi Pharmaceutical Group, to the conventional management philosophy. is. The Kobayashi Pharmaceutical Group believes that pursuing the provision of “Pleasure” for people and society in this management philosophy is the significance of the Kobayashi Pharmaceutical Group.

SSP Co., Ltd. engages in the manufacture and sale of pharmaceuticals, quasi-drugs and cosmetics. The company was founded in 1765 and is headquartered in Tokyo, Japan.

Angelini produces, markets and distributes products for the health and well-being of people. Being close to the people and meeting their daily needs with effective and reliable products, of high quality, of great diffusion and accessibility, guaranteeing a constant and tangible well-being is the mission of Angelini. His goal is expressed in a clear vision: to be the spontaneous choice in the area of ​​health and daily well-being.

Teikoku Seiyaku Co. Ltd. manufactures and distributes pharmaceuticals. It offers poultices, including Lidoderm, medicated patches and plasters, and anti-inflammatory plasters. The company also provides prescription drugs, such as Dovonex ointment, Hap Star ID, Glycerin Enema, Steronema, Bari-Enema, Magtect U, and Zikilion syrups. Teikoku Seiyaku was founded in 1848 and is headquartered in Higashi Kagawa, Japan

Hisamitsu Pharmaceutical Co., Ltd, a subsidiary of Hisamitsu Pharmaceutical Co., Inc., is a Taiwanese company located in Taipei. The firm manufactures and markets pharmaceuticals.

They want to take the world from pain to pain-free parenterals through dedicated work on creating innovations. Emal the first in the world injectable medicine against critical malaria, Etojet – the world’s first painless Etrocoxib injection and a first of it’s kind injectable Diclofenac Sodium for pain relief, are all a result of the pursuit of ideas taken to their full potential. Their aim is to make disease management easier and painless for both patients and healthcare professionals.

Shimoda Biotech (Pty) Ltd. Develops new pharmaceutical products. The products include Injectable Diclofenac, Oral Diclofenac, Alprazplam Cyclodeztrin Inclusion Complex, And Propofol Cyclodextrin Inculion Complex. The company was founded by Greg Gilbert and is located at Port Elizabeth, South Africa.

Genmedica Therapeutics SL engages in the research and development of new treatments for diabetes. Its has developed novel NCE-generating platform to generate dual action, small molecules that act against oxidative stress and inflammation, two specific pathways known to be critical in the root causes of the disease. The company was founded by Alec Humayun Mian and Luc Marti Clauzel on June 21, 2004 and is headquartered in Barcelona, Spain.

HEXAL is the German generic manufacturer and belongs to the worldwide Sandoz Group with its headquarters in Holzkirchen, Bavaria. HEXAL brings biosimilars to the German market. Biosimilars are high-differentiated products, based on very complex biological molecules. Biologics, or biopharmaceuticals, are medicines produced from living organisms using biotechnology techniques. Many biologics are recombinant proteins and are manufactured using „recombinant DNA“ technology, a process that involves inserting a specific gene into a host cell to produce a particular protein. These complex state-of-the-art molecules represent a distinct regulatory class of medicine compared to traditional, chemically synthesized medicines. In Germany HEXAL employs more then 4.000 people at six sites. The company was founded in 1986 and merged with Sandoz in 2006.

Futura Medical Developments Ltd. develops pharmaceutical products for both the prescription and consumer healthcare markets. The company is headquartered in Guildford, the United Kingdom.

Javelin Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of products for the pain management market primarily in the United States and Europe. Its products focus on treating various pain disorders ranging from acute and episodic moderate-to-severe pain associated with breakthrough cancer pain, post-operative pain, post-trauma pain (orthopedic injury pain), procedural pain, and burn pain. The company's Dyloject (injectable diclofenac) received approval for marketing to treat post-operative pain in the United Kingdom and was licensed to Therabel Pharma N.V. for commercialization in the European Union and certain other countries outside the United States. Its products in the Phase 3 development stage in the U.S. include Dyloject (diclofenac sodium injectable), an injectable formulation of diclofenac and a prescription nonsteroidal anti-inflammatory drug that is used to treat post-operative pain due to its combination of effectiveness and tolerability; Ereska (intranasal ketamine), a proprietary nasal formulation; and Rylomine (intranasal morphine) for treatment of acute moderate-to-severe pain, including breakthrough pain. Javelin Pharmaceuticals has license agreements with Shimoda Biotech, Ltd. to develop and commercialize products related to a proprietary formulation of the injectable delivery of diclofenac; and West Pharmaceutical Services, Inc. to develop and commercialize intranasal morphine for the transmucosal delivery of morphine to humans and animals for the treatment of pain. The company was founded in 1998 and is based in Cambridge, Massachusetts.